Body weight and lipid profiles.

<p>5 wks after Ang II infusion, body weight (<b>A</b>) and lipid (<b>B</b>) profiles were measured in vehicle- (white squares, n = 10) and rosuvastatin- (black squares, n = 9) treated ApoE^-/- mice. No significant differences were found between the 2 groups.</p

Effect of rosuvastatin on HO activity and AAA severity.

<p>No significant difference in HO activity between aortas from vehicle- (white squares) and rosuvastatin- (black squares) treated ApoE^-/- mice were found 14 days post-Ang II infusion, but when grouped by severity, HO activity in aortas with type-2 expansions was significantly higher in rosuvastatin-treated mice. *p<0.05, n = 3 for each group.</p

Immunohistochemical staining.

<p>(<b>A</b>) Immunohistochemical staining for Mac1 in aortae harvested from WT and HO-1 Het mice at 7 and 28 days post-PPE infusion and of heme-treated HO-1 Het mice at 28 days post-PPE infusion. (<b>B</b>) Macrophage infiltration in the aortae of WT (n = 4 and 7) and HO-1 Het (n = 4 and 7) mice at 7 and 28 days post-PPE infusion, respectively, and of heme-treated HO-1 Het mice (n = 5) at 28 days post-PPE infusion (right panel). Data shown as cells per high power field (hpf). *p<0.0001 compared to WT mice.</p

Effect of rosuvastatin on AAA severity.

<p>(<b>A</b>) Representative <i>ex vivo</i> pictures of aortas harvested from ApoE^-/- mice treated with saline-vehicle (left panel) or rosuvastatin (right panel) following Ang II infusion. (<b>B</b>) Number of pups categorized by AAA severity scores post-Ang II infusion in vehicle- (white squares) or rosuvastatin- (black squares) treated mice. (<b>C</b>) Overall AAA severity in both groups combined. *p = 0.04, n = 7 and 9 for vehicle- and rosuvastatin-treated mice, respectively.</p

Profiles of AAA development following PPE infusion.

<p>(<b>A</b>) AAA diameters were measured at baseline and at 3, 7, 14, 21, and 28 days post-PPE infusion by ultrasound in WT (white squares), HO-1 Het (black squares), heme-treated WT (white diamonds), and heme-treated HO-1 Het (black circles) mice. (<b>B</b>) Representative longitudinal ultrasound views of AAAs 28-days post-PPE infusion from HO-1 Het, heme-treated HO-1 Het, WT, and heme-treated WT mice. *p<0.015, †p = 0.0025 compared to WT and heme-treated HO-1 Het mice. n = 7 to 11 for each group.</p

HO-1 promoter activity in the aorta following PPE infusion in HO-1-<i>luc</i> mice.

<p><i>Ex vivo</i> images taken 14 days following (<b>A</b>) saline infusion (control) showing weak HO-1 promoter activity (low light intensity), and post-PPE infusion (<b>B</b>) showing high HO-1 promoter activity (strong light intensity) in the aorta.</p